A Study of Tildrakizumab in the Treatment of Genital Psoriasis (CZATCH-Genital-PsO)

Who May Qualify: - Confirmed diagnosis of psoriasis, with significant involvement of genital regions, i.e., sPGA-G greater than or equal to (\>=) 3. - Need for systemic biologic therapy based on the local country specific regulations. Tildrakizumab, in accordance with the SmPC, must be the anti-IL23p19 selected therapy before including the patient in the study. - Age 18 - 99 years. - willing to sign a consent form in writing in accordance with applicable country regulations - Patient must have plaque psoriasis affecting a body surface area (BSA) \>= 1% in a non-genital area at baseline. - Patient willing and able to fill out study questionnaires. Who Should NOT Join This Trial: - Patient appears to be unwilling or unable to comply with the requirements of the study or who, in the opinion of the investigator, should not participate in the study. - Patient exposed to any experimental treatment in the past 3 months prior to baseline. - Any condition preventing prescription of Tildrakizumab according to the SmPC, including but not restricted to any contraindication or history of hypersensitivity or intolerance. - Patient dependent on the investigator, including but not restricted to employees of the study site. - Previous treatment with Tildrakizumab. Always talk to your doctor about whether this trial is right for you.